YOUR BUSINESS AUTHORITY
Springfield, MO
YOUR BUSINESS AUTHORITY
Springfield, MO
Pharmaceutical company Novo Nordisk missed analysts' expectations for the second quarter as its Wegovy and Ozempic GLP-1 drugs faced increasing competition.
Revenue in the second quarter was roughly $11.92 billion, short of expectations of $11.97 billion.
Earnings per share came to $5.96. Analysts were looking for $6.06 per share.
Read more from Quartz.
This installment of Springfield Business Journal’s Architects & Engineers Project Report showcases 26 endeavors by area design and engineering professionals.
Banker pleads guilty to fraud scheme
Longtime employee sues Ozarks Tech, alleges retaliation
Cavender’s opens hat shop in southeast Springfield
Caterpillar to acquire John Fabick Tractor Co.
Eric Schmitt introduces Modern Skies Act
Springfield airport to cut the ribbon on $35M in construction projects